Skip to main content
Premium Trial:

Request an Annual Quote

Ribozyme Spinoff Atugen Completes $20M Financing


BERLIN--Atugen Biotechnology, a new company that has been formed as a spinoff of the target discovery and validation business of Ribozyme Pharmaceuticals, announced the completion of a $20 million initial financing round and the formal opening of its facilities on the Biomedical Research Campus of the Max Delbruck Center here. Officials said the technology transfer, which includes DNA microarray technology and associated bioinformatics, is the first to have occurred from a US biotechnology company to form a new German company as part of the German Biotechnology Initiative.

Atugen's primary goal will be to accelerate discovery and validation of therapeutic targets by providing a variety of technologies and services to utilize human genomic information. The company said it expects that the technology base transferred from Ribozyme, its substantial initial capitalization, and additional technologies it will acquire or develop, should allow it to improve the speed and certainty of identifying and validating new therapeutic targets for both corporate partners and internal use.

Financing was provided by a number of sources, including the German federal and local governments, the founding company, and venture capital firms including BB Bioventures.

Filed under

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.